Novartis

Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre
Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre
Xconomy
Novartis
IFM Tre
M&A
anti-inflammatory
inflammation
Flag link:
2 Blockbuster Gene Therapy Programs to Watch in 2019
2 Blockbuster Gene Therapy Programs to Watch in 2019
Motley Fool
gene therapy
Zolgensma
Novartis
Bluebird Bio
LentiGlobin
Flag link:
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Alzheimer's disease
Biogen
aducanumab
Otsuka
Axsome Therapeutics
Amgen
Novartis
Avanir
AVP-786
AXS-05
AMG520
Flag link:
FDA approves Novartis' Mayzent for MS
FDA approves Novartis' Mayzent for MS
BioCentury
FDA
Novartis
Mayzent
siponimod
relapsing multiple sclerosis
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
FDA
Novartis
Ascendis
Eiger BioPharmaceuticals
Proteostasis Therapeutics
Fibrocell Science
Supernus Pharmaceuticals
FibroGen
INSYS Therapeutics
Flag link:
Novartis launches COPD inhalers in China
Novartis launches COPD inhalers in China
Drug Delivery Business News
Novartis
COPD
China
Ultibro Breezhaler
Seebri Breezhaler
devices
Flag link:
Conatus and Novartis suffer another midphase NASH flop
Conatus and Novartis suffer another midphase NASH flop
Fierce Biotech
Conatus
Novartis
NASH
emricasan
clinical trials
Flag link:
Novartis says listing of Alcon eye care business expected on April 9
Novartis says listing of Alcon eye care business expected on April 9
Yahoo/Reuters
Alcon
Novartis
spinoffs
eye health
Flag link:
Novartis’ Alcon picks up PowerVision for $285m
Novartis’ Alcon picks up PowerVision for $285m
Mass Device
Novartis
Alcon
PowerVision
M&A
interocular lens
devices
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology Conference Roundup - day 1
CP Wire
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
CEO of Novartis’ generics unit quits, sparking sale speculation
CEO of Novartis’ generics unit quits, sparking sale speculation
Pharmaforum
Novartis
Sandoz
generics
M&A
Richard Francis
biosimilars
Flag link:
New insights emerge in an effort to repurpose Novartis’ cancer drug Tasigna in Parkinson’s disease
New insights emerge in an effort to repurpose Novartis’ cancer drug Tasigna in Parkinson’s disease
Fierce Biotech
Novartis
Tasigna
Parkinson's Disease
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Pharmaceutical Business Review
Novartis
Cosentyx
China
psoriasis
Flag link:
Seventure holds first close of €200M microbiome fund
Seventure holds first close of €200M microbiome fund
Fierce Biotech
Seventure Partners
microbiome
Novartis
startups
Flag link:
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
RAPS.org
Novartis
Janssen
JNJ
psoriasis
false advertising
Tremfya
Flag link:
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Fierce Pharma
JNJ
Janssen
Tremfya
psoriasis
Novartis
Cosentyx
Eli Lilly
Taltz
Flag link:
Novartis faces shareholder criticism over drug prices at AGM
Novartis faces shareholder criticism over drug prices at AGM
Yahoo/Reuters
Novartis
drug pricing
shareholders
Flag link:
Novartis first partner in RWE collaboration for dermatology
Novartis first partner in RWE collaboration for dermatology
BioCentury
Novartis
PharmaSolutions
real world evidence
dermatology
Flag link:

Pages